基于RNA干扰的疗法用于降低心血管风险
Natalia Nazarenko1, Jiyoung Seo1, Sanjana Nagraj2
1Jacobi Medical Center/Albert Einstein College of Medicine, 1400 Pelham Parkway S, The Bronx, NY 10461, USA.
Current molecular pharmacology
|March 6, 2024
概括
降低低密度脂蛋白胆固醇 (LDL-C) 对降低心血管疾病 (CVD) 风险至关重要. 虽然有效,但单独降低LDL-C可能无法完全预防重大心血管事件.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 全球心血管疾病 (CVD) 发病率正在上升,在2019年达到5.23亿例.
- 脱脂症,以异常的脂质水平为特征,是心脏病的显著可改变的风险因素,受遗传学和生活方式的影响.
- 降低低密度脂蛋白胆固醇 (LDL-C) 是降低心血管疾病风险的主要策略.
研究的目的:
- 强调LDL-C降低在控制心血管疾病中的重要性.
- 突出降低LDL-C水平对冠状动脉疾病 (CAD) 和死亡率的好处.
- 承认LDL-C降低在完全消除心血管事件风险方面的局限性.
主要方法:
- 对有关心脏病发病率趋势的流行病学数据的审查.
- 分析研究的分析,调查降脂策略的影响.
- 检查LDL-C降低与临床结果之间的关系,包括CAD和死亡率.
主要成果:
- 降低20 mg/dl的LDL-C水平与每1000个人预防2-3例CAD有关.
- 降低LDL-C水平显示出显著的死亡率益处.
- 尽管有好处,但降低LDL-C并不能消除所有重大心血管事件的风险.
结论:
- 向和降低LDL-C水平仍然是预防和管理心血管疾病的基石.
- 进一步的策略可能是必要的,以解决残留心血管风险在患有失脂血症的患者.
- 全球心血管疾病的增加强调了持续研究和有效干预的必要性.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
512
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
512
01:25Antihypertensive Drugs: Direct Renin Inhibitors
625
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
625
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523
02:15Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K